To determine the timing and actual incidence of p53 mutations in oral epithelial lesions, we examined 33 primary squamous cell carcinomas (SCCs), 14 dysplasias and six hyperplasias from Japanese patients by a combination of yeast functional assay and DNA sequencing. The assay detects mutations of p53 mRNA between codons 67 and 347 on the basis of the DNAbinding activity of the protein. Twenty-six SCCs (79%) and ®ve dysplasias (36%) were positive for p53 mutation, while all six hyperplasias were negative for the mutation. Human papillomavirus type 16 E6 mRNA was detected in one of seven p53 mutation-negative SCCs by reverse transcription polymerase chain reaction (RT ± PCR). We further examined p53 mutations in 17 Sri Lankan oral SCCs using the yeast functional assay and the singlestrand conformation polymorphism analysis of PCRampli®ed DNA fragments (PCR ± SSCP) of exon 5 ± 8. The mutations were con®rmed by DNA sequencing and the detection sensitivity was compared between the two methods. Six samples (35%) were positive for p53 mutation in PCR ± SSCP analysis, while nine samples (53%) were positive in yeast functional assay. This suggests that the incidence of p53 mutations has been considerably underestimated in the conventional SSCP analysis. The present data indicate that p53 mutations are extremely frequent in oral cancers in the Japanese, and suggest that the timing and signi®cance of p53 mutation in oral tumor progression vary in dierent ethnic populations and areas.
Introduction
Carcinogenesis is a multistep process, and thus an accumulation of several independent mutations is necessary for the progression of cancer. Recent research on genetic alterations found in human cancers has shown that inactivation of p53 tumor suppressor gene is a major step in the development of cancers Bishop, 1991) . The timing of p53 mutations has been studied best in colorectal adenocarcinoma where mutations of p53 gene most frequently occur between the stages of late adenoma and invasive carcinoma (Fearon and Vogelstein, 1990 ). Mutations of p53 have also been observed in a variety of non-invasive, dysplastic epithelial lesions from various tissues, including oral cavity (Lazarus et al., 1995; Kusama et al., 1996) , esophagus (Casson et al., 1991; Bennett et al., 1992) , and lung (Sozzi et al., 1992) . These data suggest that mutations of p53 gene may be an early event in squamous epithelium during progression to cancer.
In oral cancers, the p53 mutation rates are variable in published studies (20 ± 60%, Chiba et al., 1996; Lazarus et al., 1996; Sakai et al., 1992; Ogden et al., 1992; Sauter et al., 1992) and therefore no general conclusions have been reached with respect to the correlation between p53 status and clinical prognosis (Field et al., 1993) . This may re¯ect the sensitivity of the methods used for the detection. Two techniques are widely used to study p53 in clinical materials: screening with anti-p53 antibodies for overexpression of mutant protein (Field et al., 1991; Gusterson et al., 1991; Iggo et al., 1990; Maestro et al., 1992) and DNA structurebased screening (Orita et al., 1989; Sheeld et al., 1989) . Immunohistochemistry is reasonably sensitive and easy to implement in diagnostic laboratories. However, truncated forms of p53 resulting from frameshift and nonsense mutations are not reliably detected by this approach (Hall and Lane, 1994; SjoÈ gren et al., 1996) . Furthermore, wild-type p53 can be overexpressed without mutations (Moll et al., 1992; Cesarman et al., 1993) . Alternatives to this approach are single-strand conformation polymorphism (SSCP) (Orita et al., 1989) and denaturing gradient gel electrophoresis (DGGE) (Sheeld et al., 1989) . Although these methods are practically sensitive and widely used, they cannot distinguish among polymorphisms, functionally silent mutations, and inactivating mutations. Recently, a dierent approach based on a biological assay for p53 function has been made, which uses yeast as a living test tube (Ishioka et al., 1993; Flaman et al., 1995) . This method takes advantage that gapped plasmid is repaired by homologous recombination of the linear plasmid and DNA fragment in yeast (Orr-Weaver et al., 1983) . The p53 functional assay in which yeast change color according to the p53 status raises the very real possibility of simple and large-scale screening for p53 functional mutations (Flaman et al., 1995) in clinical samples.
In the present sudy, we de®ned the p53 status in premalignant and malignant lesions in oral cavity of Japanese patients by using yeast functional assay and DNA sequencing. The results demonstrated high frequencies of p53 mutations, at 36% and 79%, in oral dysplasias and primary squamous cell carcinomas (SCC), respectively. Although oral SCC is relatively uncommon in most parts of the world, it occupies the top rank among the cancers in Sri Lankan males (Saranath et al., 1993) . The high incidence rate of oral SCC in Sri Lanka prompted us to examine the frequency of p53 mutation in Sri Lankan SCCs using yeast functional assay. In this study we also used conventional PCR ± SSCP to compare the detection rates between these two methods.
Results

Sensitivity of yeast functional assay in detecting p53 mutations
To assess the sensitivity of yeast functional assay, wildtype p53 RT ± PCR product from KB cells and mutant p53 RT ± PCR product from KSC-1 cells were mixed at serial ratios, and yeast were cotransformed with the cDNA mixture and the gapped pSS16 plasmid. As shown in Figure 1 , a highly signi®cant positive correlation (r=0.987, P50.001) was observed between the percentage of red colonies and the content of mutant p53 cDNA. A statistically signi®cant increase (P50.01) in % of red colonies was observed when 6% of mutant p53 was present in p53 cDNA. A comparison between % red colonies given by only wild-type p53 and 17% mutant p53, 4.8+1.8% versus 17.3+3.9%, revealed a highly signi®cant dierence (P=0.001).
Detection of p53 mutations by yeast functional assay in premalignant lesions and squamous cell carcinomas of the oral cavity in Japanese
The results of yeast functional assay performed in the Japanese samples were shown in Tables 1 and 2 . Normal mucosas from healthy persons, and histologically diagnosed granulation tissues and scar tissue gave 5.3% red colonies (range: 2.9 ± 9%). For this reason, less than 10% of red colonies were regarded as background of this assay. Of 20 biopsy specimens clinically diagnosed as leukoplakia, ®ve samples gave 33 ± 85% red colonies, whose sequencing analysis revealed the presence of p53 clonal mutations (Tables  1 and 3 ). Histological classi®cation of these tissues with p53 mutation was severe dysplasia (four samples) and moderate dysplasia (one sample). Two samples of severe dysplasia (L19 and L20) which gave 13% and 9% red colonies, respectively, were analysed by DNA sequencing and no clonal p53 mutations were detected. All eight tissues classi®ed as mild dysplasia and hyperplasia gave red colonies of background level (range: 3 ± 7%). Of 33 squamous cell carcinomas (SCCs) 26 (79%) gave more than 17% of red colonies and seven gave red colonies of background level (range: 3 ± 10%). Three samples (T3, T9 and T15) which gave 17 ± 19% red colonies and seven samples which gave 24 ± 94% red colonies were subjected to sequencing analysis. In all samples giving more than 17% red colonies, p53 clonal mutations were demonstrated (Table 3) . Results of yeast functional assay in 61 oral specimens were summarized in Figure 2 . Of 53 samples from premalignant and malignant lesions, ®ve samples were derived from two patients with multiple oral lesions. In one patient, a dysplastic lesion (L14) was located topologically adjacent to an invasive carcinoma (T14). Both lesions had an identical p53 missense mutation at codon 176. In the other patient, p53 alterations were not detected in two dysplastic lesions (L18 and L20), but an invasive carcinoma (T23) lying distant from both dysplastic lesions had p53 alteration at codon 152.
Determination of cut-o value for p53 mutation in yeast functional assay A summary of data obtained by yeast functional assay and DNA sequencing was shown in Table 3 . Clonal mutations were observed in all samples giving more Figure 1 Relationship between the content of mutant p53 cDNA and the percentage of red colonies in yeast functional assay. A positive correlation was observed between the content of mutant p53 cDNA and % of red colonies, which was evaluated by simple regression based on the following formula. y=4.9618+0.69268x; r=0.987 *P50.01, **P=0.001, compared with % of red colonies given by PCR-ampli®ed wild-type p53 cDNA only p53 mutations in oral epithelial lesions H Kashiwazaki et al than 17% of red colonies, whereas no clonal mutations were found in samples giving 13% and 9% of red colonies. Based on the data concerning sensitivity of this assay ( Figure 1 ) and clonality of p53 mutation (Table 3) , we chose 17% of red colonies as cut-o value for p53 mutation ( Figure 2 ). Of the 15 mutations detected by sequencing, nine were G to A transition and four were G to T transversion. Two of four mutations in severe dysplasias were found at codon 273, a mutational hot spot.
Detection of HPV-DNA and E6 mRNA in p53 mutation-negative SCCs
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His ¡ Arg Arg ¡ stop Gln ¡ stop Gly ¡ Ser 3/3 3/3 2/3 3/3 3/3 2/3 3/3 3/3 2/3 3/3 2/3 2/3 4/4 2/3 2/4 0/3 0/4 p53 mutations in oral epithelial lesions H Kashiwazaki et al 32 P-labeled HPV-16 E6 DNA (data not shown). In addition, HPV-DNA detection and typing were attempted using PCR with`high risk group' HPVspeci®c primers in T1, T2, T6, T12 and T16 but no ampli®cation of HPV-DNA were obtained.
p53 functional mutations in oral SCC and their correlation with the clinical features in the Japanese patients
We analysed correlation between clinical data and percentage of red colonies. p53 mutation was not signi®cantly associated with age, sex, tumor size, nodal status, histological dierentiation or invasiveness. However, histologically diagnosed lymph node metastasis was signi®cantly increased in cases giving more than 50% of red colonies (2/10 versus 7/10, P50.05).
Comparison of the detectability of p53 mutations by yeast functional assay and PCR ± SSCP in oral SCC in Sri Lanka
Since oral cancer is the most common of all cancers in Sri Lanka, we investigated p53 status in Sri Lankan oral cancers by yeast functional assay, employing the cut-o value which has been determined above. The split form of the assay was also performed to con®rm clonal mutation in the cases presenting 12 ± 17% of red colonies. In addition, PCR ± SSCP analysis was performed in the same clinical materials. Seventeen squamous cell carcinomas from Sri Lankan patients were tested by both methods and the results were compared (Table 4) . Six samples (35%) showed extra bands in PCR ± SSCP analysis, while nine samples (53%) presented more than 17% red colonies in yeast functional assay. The samples classi®ed as p53 mutation-positive were subjected to DNA sequencing analysis to con®rm the mutations. Out of six samples which were classi®ed as mutation-positive by PCR ± SSCP analysis, four samples (S1, S10, S12 and S14) were determined to have mutations in exons 5 and 7, and two samples (S4 and S9) were not con®rmed to have mutations in exon 5 by direct sequencing. Among the samples which were classi®ed as mutation-positive by yeast functional assay, one sample (S8) had a mutation in exon 4, ®ve samples (S4, S9, S12, S14 and S16) in exon 5, two samples (S1 and S10) in exon 7, and one sample (S2) in exons 4 and 8. Because exon 4 was not covered by PCR ± SSCP in this study, we compared the sensitivity of the two methods for detecting p53 mutations in exon 5 ± 8. The mutations were detected in 6/16 (38%) by PCR ± SSCP and in 8/ 16 (50%) by yeast functional assay. Band shifts were not observed in the base changes of AAG to AAT at codon 305 and TGC to TGG at codon 176 in PCR ± Figure 2 The frequency of p53 mutations in premalignant and malignant oral epithelial lesions in Japanese. *, background level of red colonies; *, p53 mutation positive by yeast functional assay;
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Discussion
We have demonstrated that p53 mutations, de®ned by yeast functional assay and sequencing analysis, are found in 79% of primary oral SCCs from the Japanese patients. This rate is very high compared with only 24% in the previous study performed by PCR ± SSCP method (Chiba et al., 1996) . Obviously this dierence re¯ects the higher sensitivity of the yeast assay because both studies were performed in the same geographical area. The incidence of p53 mutations described here (79%) also diers signi®cantly from overall incidence (47%) in oral cancers reported previously in Western countries (Paterson et al., 1996) . The high sensitivity of the yeast assay was brought about by a combination of several factors: A larger region of the p53 cDNA (codons 67 ± 347) is tested than in most DNA structure-based screening methods. The p53 mutations are detectable when more than 6% of mutant p53 cDNA is present in the mixture of wild-type and mutant p53 cDNA. We determined the reliable cut-o value for p53 mutation in this assay on the basis of clonality of the mutation. Clonal p53 mutations were demonstrated by sequencing analysis in the samples giving a value higher than 17% red colonies. A similar result has been reported in human malignant astrocytic neoplasms (Tada et al., 1997) . Although we set a cuto value at 17% in this experiment, clonality of p53 mutation decreased sharply from nearly 100 to 0% in the samples giving 19 ± 13% red colonies. Therefore, we estimated that 20% red colonies should be acceptable and clinically safe cut-o point for detecting p53 mutation without sequencing analysis. It is known that transactivation function of the p53 protein is abrogated not only by intragenic mutations of p53 but also by complex formation with oncogenic HPV E6 protein (Schener et al., 1990) . We detected the presence of HPV-16 E6 mRNA in one of seven p53 mutation-negative samples. Overall, 82% of primary oral SCCs from the Japanese patients was associated with loss of p53 function. The timing of p53 mutations during tumor progression has been studied by determining p53 mutation rates in premalignant lesions of various tissues such as those of the lung (Sozzi et al., 1992) , and esophagus (Casson et al., 1991; Bennett et al., 1992) . We determined the frequency of p53 mutations in premalignant lesions of the oral cavity. The histological grade of malignancy was positively correlated to the frequency of p53 mutation. In six hyperplastic lesions without dysplasia, no p53 mutations were detected. In contrast, in 14 displastic lesions, 36% was positive for p53 mutation (Figure 2) . Although relatively few studies have been made as to p53 mutations in oral premalignant lesions, 15.4% (Lazarus et al., 1995) or 27% (Kusama et al., 1996) of epithelial dysplasia has been reported to be positive for p53 mutation. Since it has been shown that the malignant potential of leukoplakia is as high as 23 ± 38% (Silverman et al., 1984) , mutations of the p53 gene may be indicative of the potential of these lesions to develop into SCC. This is suggested by our ®nding that one dysplastic lesion (L14) was located topologically adjacent to an invasive carcinoma (T14) and both lesions had an identical p53 mutation at codon 176. This mutation at codon 176 was most frequently observed in SCCs. In addition, we found two mutations in dysplasia at codon 273 which is known as a mutational hot spot in many cancers and an adduct hot spot of benzo[a]pyrene metabolites in lung cancers (Denissenko et al., 1996) . The mutations identi®ed by DNA sequencing were predominantly G : C to A : T transitions (9/15) or G : C to T : A transversions (4/15). G to A transitions and deletions were the predominant mutations observed in oral cavity SCCs from tobacco users (Lazarus et al., 1996) .
In Western countries, approximately 1% of all cancers are oral in origin, whereas in India and Sri Lanka, oral cancer comprises 35 ± 40% of all malignancies, which is due to the habit of tobacco chewing in betel quid (Saranath et al., 1993) . A striking dierence has been reported in the frequency of p53 mutations, which are infrequent in oral cancers in the Indian subcontinent (7%) but are common in oral cancers in Western countries (47%) (Paterson et al., 1996) . We used both yeast assay and PCR ± SSCP analysis for detecting p53 mutations in 17 samples from Sri Lankan patients. The detection rate was higher in yeast assay (53%) than PCR ± SSCP (35%). In two samples, p53 mutations were detected in exon 4 by yeast functional assay but not by PCR ± SSCP because exon 4 was not covered by routine PCR ± SSCP analysis due to codon 72 polymorphism. When compared the sensitivity of the two methods in exon 5 ± 8, 38% of mutations was detected by PCR ± SSCP and 50% by yeast assay. This dierence is attributable to the fact that SSCP conditions are highly empirical and some mutations do not cause mobility shift of mutated fragment in SSCP analysis (Moyret et al., 1994) . The incidence of p53 alteration in oral cancers from the Sri Lankan patients, de®ned by yeast assay, was very high compared to that previously reported in Sri Lanka (7.3%) and India (21%) (Paterson et al., 1996; Munirajan et al., 1996) , though still signi®cantly lower than that from the Japanese patients (79%). These results suggest that the p53 gene is important as a target for mutation in the early stage of oral carcinogenesis in Japanese patients, and that the timing and signi®cance of p53 mutation in oral tumor progression vary in dierent ethnic populations and areas.
Materials and methods
Clinical samples and cell lines
Thirty-three Japanese and 17 Sri Lankan patients, diagnosed as having squamous cell carcinoma (SCC) of the oral cavity, were investigated for p53 mutations. Fresh primary tumors were obtained following biopsy or surgical resection at the Department of Oral Surgery, Hokkaido University Dental Hospital, Japan and four hospitals in Sri Lanka (Anuradhapura General Hospital, Kurunegala General Hospital, Maharagama Cancer Institute, and Dental Institute in Colombo). The study also included six hyperplasias, 14 dysplasias and eight noncancerous tissues (four normal oral mucosas, three granulation tissues and one scar tissue) from Japanese patients. The tissues were p53 mutations in oral epithelial lesions H Kashiwazaki et al quickly frozen in liquid nitrogen and stored at 7808C until use. None of the procedures to enrich the samples for tumor cells was done in this study. To assess the sensitivity of p53 functional assay, two human oral SCC cell lines (KSC-1 with p53 mutation at codon 263 and KB with wildtype p53) were used. KSC-1 was established from a surgically resected tumor tissue. KB was obtained from the Japanese Cancer Research Resources Bank.
RNA extraction and reverse transcription (RT) ± PCR
Total RNA was extracted from tissue samples. Approximately 100 mg of tumor tissue or 1610 7 cells were homogenized in 2 ml Trizol reagent (Gibco-BRL, Tokyo, Japan), mixed with 0.4 ml of chloroform and centrifuged. The supernatant was collected and the total RNA was precipitated with isopropylalcohol. The precipitate was washed with 75% ethanol and dissolved with 40 ml water containing 0.1% diethyl pyrocarbonate (WAKO, Osaka, Japan). RNA integrity was veri®ed by electrophoresis in a 1% agarose gel. p53 cDNA was synthesized at 378C for 1 h by 200 units of Moloney murine leukemia virus (MMLV) reverse transcriptase (Gibco-BRL) from 3 mg of total RNA in 20 ml of RT buer containing 25 pmol p53-speci®c primer RT-1, (5'-CGGGAGGTAGAC-3'), 7.5 mM dithiothreitol (DTT), 0.5 mM MgCl 2 and 0.5 mM dNTPs (Tada et al., 1996) . The p53 cDNA was ampli®ed in 20 ml of reaction mixture containing 2 ml of RT reaction product, 1.25 units of pfu DNA polymerase (Stratagene, La Jolla, CA), 10 pmol of primers, 10% dimethylsulfoxide and 50 mM dNTPs. For the standard p53 functional assay, primers P3 (5'-ATTTGATGCTGTCCCCGGACGATATT-GAA(s)C-3', where (s) represents a phosphorothioate linkage) and P4 (5'-ACCCTTTTTGGACTTCAGGTGG-CTGGAGT(s)G-3') were used. For the split form of the assay, primers P3 and P17 (5'-GCCGCCCATGCAG-GAACTGTTACACA(s)T-3'), or primers P4 and P16 (5' -GCGATGGTCTGGCCCCTCCTCAGCATCTT (s) A-3') were used as described . PCRs were run in the Thermal Cycler Model 2400 (Perkin-Elmer, Chiba, Japan) at 968C for 1 min; then 35 cycles of 958C for 40 s, 658C for 70 s, and 788C for 90 s followed by 788C for 2 min. Satisfactory ampli®cation was con®rmed by examining the PCR product on a 1% agarose gel. Each crude PCR product was used for yeast transformation.
Plasmids
The yeast expression vectors pSS16 (Ishioka et al., 1993) was digested with excess amounts of HindIII and StuI and electrophoresed on 1% low melting temperature agarose (Sea Plaque agarose; FMC, Rockland, ME). The linearized plasmids were recovered from the gel, dephospholized with calf intestinal alkaline phosphatase (Takara, Otsu, Japan) and puri®ed with Wizard PCR prep kit (Promega, Madison, WI). The gap was created between codons 67 and 347 (Ishioka et al., 1993) . For the split form of the assay, two plasmids, pFW34 and pFW35, were used. The gaps were created between codons 66 and 211 (BglII and SmaI sites) in pFW35 and between codons 210 and 348 (BglII and StuI sites) in pFW34 .
Yeast p53 functional assay
The yeast functional assay was performed according to the method modi®ed by Tada et al. (1996) . The yeast reporter strain yIG397 (Flaman et al., 1995) was used throughout this study. The genotype is MATaade 2-1 leu2-3, 112trp1-1his3-11, 15can1-100ura3-1 URA3 36RGC::pCYC1::ADE2. The strain yIG397 contains an integrated plasmid with the ADE2 open reading frame under the control of a p53-responsive promoter. When the strain is transformed with a plasmid encoding p53, the cells fail to express ADE2 and form red colonies because of the accumulation of an intermediate in adenine metabolism (Stotz and Linder, 1990 ). Yeast were cultured in 100 ml of YPD medium supplemented with 200 mg/ml of adenine, until OD600 reached 0.8. The cells were pelleted, resuspended in 10 ml of LiOAc solution containing 0.1 M lithium acetate, 10 mM Tris-HCl pH 8.0, and 1 mM EDTA Na 2 , pelleted again and resuspended in 500 ml of LiOAc solution. For each transformation, 50 ml of yeast suspension was mixed with 1 ± 5 ml of unpuri®ed p53 cDNA PCR product, 50 ± 100 ng of linearized plasmid, 5 ml of sonicated single-stranded salmon sperm DNA (10 mg/ml) and 300 ml of LiOAc containing 40% of polyethylene glycol 4000 (Kanto Chemical, Tokyo, Japan). The mixture was incubated at 308C for 30 min and heat-shocked at 428C for 15 min. Yeast were then pelleted and resuspended with 100 ml of the supernatant and plated on synthetic minimal medium minus leucine plus adenine (5 mg/ml) and incubated for 48 h in a 308C humidiated chamber. More than 200 colonies were examined in this assay. When the % red colonies was 11 ± 20%, the assay was repeated and the mean value was presented.
Recovery of p53 plasmids from yeast and DNA sequencing
Yeast were digested with zymolyase (Seikagaku-Kogyo, Tokyo, Japan), and p53 expression plasmids were extracted by alkaline lysis method (QIAprep plasmid kit, QIAGEN GmbH, Hilden, Germany) and transformed into XL-1blue E.coli by electroporation. Plasmids were recovered, puri®ed and sequenced with a DyeDeoxy Terminator kit (PerkinElmer, Urayasu, Japan) on an ABI 373A automated sequencer (Applied Biosystems, Urayasu, Japan) using conditions according to the manufacturer's protocol and the following primers: P3seq, 5'-ATTTGA-TGCTGTCCCCGGACGATATTGAAC-3'; P11seq, 5'-TA-CTCCCCTGCCCTCAACAAGATG -3'; P12seq, 5'-TTG-CGTGTGGAGTATTTGGATGAC-3'; P13seq, 5'-GCCC-ATCCTCACCATCATCACACT-3'.
PCR-single-strand conformation polymorphism (SSCP) analysis and direct sequencing Each tumor specimen from Sri Lankan patients was divided into two, one for DNA preparation and the other for RNA preparation. Genomic DNA was extracted as described (Chiba et al., 1990) and ampli®ed for each of exons 5 ± 8 of the p53 gene with PCR. The primers used for PCR were as follows: exon 5, 5'-TGTTCACTTGTGCCCT-GACT-3' and 5'-CAGCCCTGTCGTCTCTCCAG-3'; exon 6, 5'-GCCTCTGATTCCTCACTGAT-3' and 5'-TTAAC-CCCTCCTCCCAGAGA-3'; exon 7, 5'-ACTGGCCTCAT-CTTGGGCCT-3' and 5'-TGTGCAGGGTGGCAAGG-TGGC-3'; exon 8, 5'-TAAATGGGACAGGTAGGACC-3' and 5'-TCCACCGCTTCTTGTCCTGC-3'. PCR amplification was performed for 35 cycles of 948C for 1 min, 608C for 2 min and 728C for 30 s followed by 7 min extension at the end (Chiba et al., 1996) . The SSCP analysis was performed as described previously (Orita et al., 1989) . Brie¯y, 0.5 ml of [a-32 P]dCTP (3000 Ci/mmol) (ICN Biochemicals, Irvine, CA) was added directly to the 20 ml of PCR reaction mixture during ampli®cation. The reaction mixture was then diluted 100-fold and subjected to SSCP analysis using a 6% polyacrylamide gel with 5% glycerol. Electrophoresis was carried out at 25 W for 4 ± 5 h at 48C. The gel was dried on ®lter paper and exposed to X-ray ®lm at 7808C. DNAs were extracted from abnormal bands and directly sequenced using [
35 S]dATP and Sequenase Kit (US Biochemical Corp, Cleveland, OH) as described previously (Chiba et al., 1996) .
Detection of HPV-DNA and E6 mRNA
For detection of human papillomavirus (HPV) DNA, genomic DNA was ampli®ed by PCR using consensus primers for malignant type HPV (i.e. , and -58) as described (Fujinaga et al., 1991) . The primers used for PCR were 5'-TGTCAAAAACCGT-TGTGTCC-3' and 5'-GAGCTGTCGCTTAATTGCTC-3' (Fujinaga et al., 1991) .
HPV-16 E6 mRNA was detected by the nested RT ± PCR using the primers as followes: E6c (5'-GGGAATCCA-TATGCTGTATG-3') and E6b (5'-CGTGTTCTTGATGA-TCTGCAA-3') for ®rst PCR, E6a (5'-TCAAAAGCCACT-GTGTCCTG-3') and E6b for second PCR (Maitland et al., 1989) . The ampli®ed products were further con®rmed by digestion pattern of AvaII and Southern blot analysis using 32 P-labeled HPV-16 E6 DNA fragment probe (nucleotides 24 ± 654).
Clinical data
For the clinical staging of the disease, the 1987 classi®cation of UICC was used (Hermanek and Sobin, 1987) . Resected tumors were histologically classi®ed according to the WHO histological typing system (Wahi and Cohen, 1971 ).
Statistical analysis
Statistical signi®cance was evaluated by the Student's ttest and the chi-square test. Data are expressed as means+s.d. Dierences were considered signi®cant at P50.05. Correlation between the % of red colonies and the content of mutant p53 cDNA was analysed by regression analysis.
